Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/15/1/100/333197/mdh025.pdf
Reference11 articles.
1. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer;ten Bokkel Huinink;J Clin Oncol,1997
2. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer;Gore;Eur J Cancer,2002
3. Recurrent epithelial ovarian carcinoma: a randomised phase III study of pegylated liposomal doxorubicin versus topotecan;Gordon;J Clin Oncol,2001
4. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer;Gore;J Clin Oncol,2001
5. Geneva;WHO Handbook for Reporting Results of Cancer Treatment,1979
Cited by 102 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Antibody-Drug Conjugates: The New Treatment Approaches for Ovarian Cancer;Cancers;2024-07-15
2. Dendritic cell immunotherapy and topotecan-based metronomic chemotherapy in ovarian cancer — a case study and literature review;Oncology in Clinical Practice;2024-01-24
3. Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer;Holland‐Frei Cancer Medicine;2022-10-21
4. Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research;Frontiers in Oncology;2022-03-25
5. Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer;International Journal of Clinical Oncology;2022-01-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3